Compare Baidu Inc (BIDU) vs 10X Genomics Inc (TXG) Price & Performance

Baidu (BIDU) trades at $104.68, down 1.19% on the day, with a bearish technical signal from moving averages and mixed oscillators. Recent earnings show a Q1 2026 miss after two prior beats, while revenue declined to $129.08B in 2025. The company is advancing AI initiatives, including Apollo Go robotaxi testing in London with Lyft's Freenow, amid analyst optimism with a 75% buy rating and $169.80 consensus price target.

Baidu presents a high-risk opportunity with strong analyst support but faces profitability pressures, as net margin fell to 1.02% in 2025. Key risks include Chinese regulatory uncertainty, competitive AI landscape, and volatile cash flows, with negative net cash flow of $11.76B in 2025. The stock's current discount to analyst targets offers potential upside if AI investments yield growth.

TXG trades at $58.15, down 0.5% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 earnings beating estimates, with revenue of $151 million and a loss per share of $0.14 versus an expected $0.24 loss. Gross margin improved to 70.03%, and cash flow from operations strengthened to $136 million in 2025. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook is mixed: analyst consensus is a Hold with a $48.38 price target below current levels, indicating caution despite recent earnings beats. Risks include persistent net losses, high valuation multiples like a P/S of 11.95, and competitive pressures in life sciences. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce holdings.